Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Epetraborole (LeuRS Inhibitor) in M. Abscessus Lung Disease. The expected timing is based on the latest available company guidance and may change.
11/12/25:- Supporting design of M. abscessus IIT, with enrollment expected to begin in early 2026. 01/12/26:- FDA cleared OHSU IIT IND; Ph2 enrollment expected to start in Q1 2026. 03/17/26:- Phase 2 OHSU investigator-initiated trial enrollment expected Q1 2026; topline results planned for late 2027. 03/31/26:- Ph2 OHSU IIT initiated; screening started (NCT07301320). Topline Ph2 data planned Late 2027. 05/11/26:- Confirms Ph2 IIT screening ongoing; topline M. abscessus data still expected in late 2027. 08/11/26:- Ph2 OHSU IIT enrollment ongoing; topline results still expected Late 2027.
Verification
Confirm timing and program details against the company announcement or filing.